Pharmacophore-based virtual screening.

This chapter is a review of the most recent developments in the field of pharmacophore modeling, covering both methodology and application. Pharmacophore-based virtual screening is nowadays a mature technology, very well accepted in the medicinal chemistry laboratory. Nevertheless, like any empirical approach, it has specific limitations and efforts to improve the methodology are still ongoing. Fundamentally, the core idea of "stripping" functional groups of their actual chemical nature in order to classify them into very few pharmacophore types, according to their dominant physico-chemical features, is both the main advantage and the main drawback of pharmacophore modeling. The advantage is the one of simplicity - the complex nature of noncovalent ligand binding interactions is rendered intuitive and comprehensible by the human mind. Although computers are much better suited for comparisons of pharmacophore patterns, a chemist's intuition is primarily scaffold-oriented. Its underlying simplifications render pharmacophore modeling unable to provide perfect predictions of ligand binding propensities - not even if all its subsisting technical problems would be solved. Each step in pharmacophore modeling and exploitation has specific drawbacks: from insufficient or inaccurate conformational sampling to ambiguities in pharmacophore typing (mainly due to uncertainty regarding the tautomeric/protonation status of compounds), to computer time limitations in complex molecular overlay calculations, and to the choice of inappropriate anchoring points in active sites when ligand cocrystals structures are not available. Yet, imperfections notwithstanding, the approach is accurate enough in order to be practically useful and actually is the most used virtual screening technique in medicinal chemistry - notably for "scaffold hopping" approaches, allowing the discovery of new chemical classes carriers of a desired biological activity.

[1]  Horvath Dragos,et al.  Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. , 2009, Journal of chemical information and modeling.

[2]  I. Bahar,et al.  Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. , 2009, Journal of medicinal chemistry.

[3]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[4]  M. Taha,et al.  Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. , 2008, Journal of medicinal chemistry.

[5]  Salvatore Cannistraro,et al.  Docking study and free energy simulation of the complex between p53 DNA‐binding domain and azurin , 2007, Journal of molecular recognition : JMR.

[6]  Valerie J. Gillet,et al.  SPROUT: A program for structure generation , 1993, J. Comput. Aided Mol. Des..

[7]  Thierry Langer,et al.  Efficient overlay of small organic molecules using 3D pharmacophores , 2007, J. Comput. Aided Mol. Des..

[8]  Thierry Langer,et al.  Comparative Analysis of Protein-Bound Ligand Conformations with Respect to Catalyst's Conformational Space Subsampling Algorithms , 2005, J. Chem. Inf. Model..

[9]  Maykel Pérez González,et al.  Variable selection methods in QSAR: an overview. , 2008, Current topics in medicinal chemistry.

[10]  Dragos Horvath,et al.  Fuzzy Tricentric Pharmacophore Fingerprints. 2. Application of Topological Fuzzy Pharmacophore Triplets in Quantitative Structure-Activity Relationships , 2008, J. Chem. Inf. Model..

[11]  Gert Thijs,et al.  Pharao: pharmacophore alignment and optimization. , 2008, Journal of molecular graphics & modelling.

[12]  Philip M. Dean,et al.  QUASI: A Novel Method for Simultaneous Superposition of Multiple Flexible Ligands and Virtual Screening Using Partial Similarity , 2007, J. Chem. Inf. Model..

[13]  Gerald M. Maggiora,et al.  On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..

[14]  A. Good,et al.  3-D pharmacophores in drug discovery. , 2001, Current pharmaceutical design.

[15]  Olivier Sperandio,et al.  Combining Ligand- and Structure-Based Methods in Drug Design Projects , 2008 .

[16]  John H. Van Drie,et al.  Computer-aided drug design: the next 20 years , 2007, J. Comput. Aided Mol. Des..

[17]  Jiabo Li,et al.  CAESAR: A New Conformer Generation Algorithm Based on Recursive Buildup and Local Rotational Symmetry Consideration , 2007, J. Chem. Inf. Model..

[18]  Dimitris K. Agrafiotis,et al.  A self‐organizing algorithm for molecular alignment and pharmacophore development , 2008, J. Comput. Chem..

[19]  J. Ponder,et al.  Force fields for protein simulations. , 2003, Advances in protein chemistry.

[20]  D. Ritchie,et al.  Protein docking using spherical polar Fourier correlations , 2000, Proteins.

[21]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[22]  D Horvath,et al.  From hit to lead. Combining two complementary methods for focused library design. Application to mu opiate ligands. , 2001, Journal of medicinal chemistry.

[23]  Federico Corelli,et al.  New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. , 2009, Journal of medicinal chemistry.

[24]  Maxim Totrov,et al.  Atomic Property Fields: Generalized 3D Pharmacophoric Potential for Automated Ligand Superposition, Pharmacophore Elucidation and 3D QSAR , 2007, Chemical biology & drug design.

[25]  Thomas Sander,et al.  Flexophore, a New Versatile 3D Pharmacophore Descriptor That Considers Molecular Flexibility , 2008, J. Chem. Inf. Model..

[26]  Eric J. Martin,et al.  Surrogate AutoShim: Predocking into a Universal Ensemble Kinase Receptor for Three Dimensional Activity Prediction, Very Quickly, without a Crystal Structure , 2008, J. Chem. Inf. Model..

[27]  Ingo Muegge Synergies of virtual screening approaches. , 2008, Mini reviews in medicinal chemistry.

[28]  P. Goodford A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[29]  Nicolas Foloppe,et al.  Conformational Sampling of Druglike Molecules with MOE and Catalyst: Implications for Pharmacophore Modeling and Virtual Screening , 2008, J. Chem. Inf. Model..

[30]  Suzanne C Brewerton,et al.  The use of protein-ligand interaction fingerprints in docking. , 2008, Current opinion in drug discovery & development.

[31]  Xicheng Wang,et al.  Cyndi: a multi-objective evolution algorithm based method for bioactive molecular conformational generation , 2009, BMC Bioinformatics.

[32]  C. Griesinger,et al.  Specific methyl group protonation for the measurement of pharmacophore-specific interligand NOE interactions. , 2008, Chemistry.

[33]  B Montgomery Pettitt,et al.  The dewetting transition and the hydrophobic effect. , 2007, Journal of the American Chemical Society.

[34]  Valerie J. Gillet,et al.  Incorporating partial matches within multiobjective pharmacophore identification , 2006, J. Comput. Aided Mol. Des..

[35]  yderis p,et al.  ISI Web of Knowledge. , 2013 .

[36]  H. Prinz How to identify a pharmacophore. , 2008, Chemistry & biology.

[37]  Paul Watson,et al.  Naïve Bayes Classification Using 2D Pharmacophore Feature Triplet Vectors , 2008, J. Chem. Inf. Model..

[38]  Alexander D. MacKerell,et al.  Comparison of protein force fields for molecular dynamics simulations. , 2008, Methods in molecular biology.

[39]  J. A. Grant,et al.  A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape , 1996, J. Comput. Chem..

[40]  Anton J. Hopfinger,et al.  Rational Design and 3D-Pharmacophore Mapping of 5′-Thiourea-Substituted α-Thymidine Analogues as Mycobacterial TMPK Inhibitors , 2009, J. Chem. Inf. Model..

[41]  Gisbert Schneider,et al.  Structure‐Based Pharmacophore Screening for Natural‐Product‐Derived PPARγ Agonists , 2009, Chembiochem : a European journal of chemical biology.

[42]  Gregory A Landrum,et al.  Conformation mining: an algorithm for finding biologically relevant conformations. , 2005, Journal of medicinal chemistry.

[43]  Anders Karlén,et al.  Is it possible to increase hit rates in structure-based virtual screening by pharmacophore filtering? An investigation of the advantages and pitfalls of post-filtering. , 2008, Journal of molecular graphics & modelling.

[44]  Michiko Amano,et al.  Novel Method for the Evaluation of 3D Conformation Generators , 2009, J. Chem. Inf. Model..

[45]  Nanda Ghoshal,et al.  An efficient tool for identifying inhibitors based on 3D-QSAR and docking using feature-shape pharmacophore of biologically active conformation--a case study with CDK2/cyclinA. , 2008, European journal of medicinal chemistry.

[46]  Kyoung Tai No,et al.  Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. , 2009, Bioorganic & medicinal chemistry.

[47]  Ruth Nussinov,et al.  Principles of docking: An overview of search algorithms and a guide to scoring functions , 2002, Proteins.

[48]  K. Zhao,et al.  A three-dimensional pharmacophore model for RXRα agonists , 2009 .

[49]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[50]  Chris G. Kruse,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[51]  Yu Xue,et al.  MBA: a literature mining system for extracting biomedical abbreviations , 2009, BMC Bioinformatics.

[52]  Olivier Sperandio,et al.  MED-3DMC: a new tool to generate 3D conformation ensembles of small molecules with a Monte Carlo sampling of the conformational space. , 2009, European journal of medicinal chemistry.

[53]  David W. Ritchie,et al.  Discovery of Novel HIV Entry Inhibitors for the CXCR4 Receptor by Prospective Virtual Screening , 2009, J. Chem. Inf. Model..

[54]  D. Douguet Ligand-Based Approaches in Virtual Screening , 2008 .

[55]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[56]  Thierry Langer,et al.  Comparative Performance Assessment of the Conformational Model Generators Omega and Catalyst: A Large-Scale Survey on the Retrieval of Protein-Bound Ligand Conformations , 2006, J. Chem. Inf. Model..

[57]  Y. Kurogi,et al.  Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. , 2001, Current medicinal chemistry.

[58]  Wolfgang Guba,et al.  Recent developments in de novo design and scaffold hopping. , 2008, Current opinion in drug discovery & development.

[59]  Thomas Sander,et al.  Comparison of Ligand- and Structure-Based Virtual Screening on the DUD Data Set , 2009, J. Chem. Inf. Model..

[60]  Areej M. Abu Hammad,et al.  Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and Shape-Complemented in Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors , 2009, J. Chem. Inf. Model..

[61]  Hans Matter,et al.  Comparing 3D Pharmacophore Triplets and 2D Fingerprints for Selecting Diverse Compound Subsets , 1999, J. Chem. Inf. Comput. Sci..

[62]  Weifan Zheng,et al.  Novel Approach to Structure-Based Pharmacophore Search Using Computational Geometry and Shape Matching Techniques , 2008, J. Chem. Inf. Model..

[63]  David Baker,et al.  Protein-protein docking with backbone flexibility. , 2007, Journal of molecular biology.

[64]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[65]  Heather A Carlson,et al.  Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.

[66]  D. Horvath,et al.  G-protein-coupled receptor affinity prediction based on the use of a profiling dataset: QSAR design, synthesis, and experimental validation. , 2005, Journal of medicinal chemistry.

[67]  Dragos Horvath,et al.  Development and Validation of a Pharmacophore‐Based QSAR Model for the Prediction of CNS Activity , 2009, ChemMedChem.

[68]  S Vadivelan,et al.  Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. , 2009, European journal of medicinal chemistry.

[69]  Dragos Horvath,et al.  QSAR Strategy and Experimental Validation for the Development of a GPCR Focused Library , 2005 .

[70]  W L Jorgensen,et al.  Rusting of the lock and key model for protein-ligand binding. , 1991, Science.

[71]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[72]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[73]  Hongma Sun,et al.  Pharmacophore-based virtual screening. , 2008, Current medicinal chemistry.

[74]  Atul J. Butte,et al.  The "etiome": identification and clustering of human disease etiological factors , 2009, BMC Bioinformatics.

[75]  David E. Clark,et al.  PRO_SELECT: Combining structure-based drug design and combinatorial chemistry for rapid lead discovery. 1. Technology , 1997, J. Comput. Aided Mol. Des..

[76]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[77]  David A. Evans,et al.  Predicting the Accuracy of Ligand Overlay Methods with Random Forest Models , 2008, J. Chem. Inf. Model..

[78]  Gisbert Schneider,et al.  PhAST: pharmacophore alignment search tool , 2009, J. Comput. Chem..

[79]  P. Charifson,et al.  Conformational analysis of drug-like molecules bound to proteins: an extensive study of ligand reorganization upon binding. , 2004, Journal of medicinal chemistry.

[80]  Thierry Langer,et al.  Fast and Efficient in Silico 3D Screening: Toward Maximum Computational Efficiency of Pharmacophore-Based and Shape-Based Approaches , 2007, J. Chem. Inf. Model..

[81]  Todd J. A. Ewing,et al.  Critical evaluation of search algorithms for automated molecular docking and database screening , 1997 .

[82]  Ying Leng,et al.  Structure-based virtual screening for identification of novel 11 beta-HSD1 inhibitors , 2009 .

[83]  Igor V. Tetko,et al.  Critical Assessment of QSAR Models of Environmental Toxicity against Tetrahymena pyriformis: Focusing on Applicability Domain and Overfitting by Variable Selection , 2008, J. Chem. Inf. Model..

[84]  Jaime Rubio-Martinez,et al.  Mimicking direct protein–protein and solvent-mediated interactions in the CDP-methylerythritol kinase homodimer: a pharmacophore-directed virtual screening approach , 2009, Journal of molecular modeling.

[85]  Michael R Shirts,et al.  Parallelized-over-parts computation of absolute binding free energy with docking and molecular dynamics. , 2006, The Journal of chemical physics.

[86]  Benjamin Parent,et al.  Fuzzy Tricentric Pharmacophore Fingerprints, 1. Topological Fuzzy Pharmacophore Triplets and Adapted Molecular Similarity Scoring Schemes , 2006, J. Chem. Inf. Model..

[87]  J. Mason,et al.  New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.

[88]  Ying Leng,et al.  Structure-based virtual screening for identification of novel 11beta-HSD1 inhibitors. , 2009, European journal of medicinal chemistry.

[89]  Luhua Lai,et al.  Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.

[90]  Cristina Tintori,et al.  Targets Looking for Drugs: A Multistep Computational Protocol for the Development of Structure-Based Pharmacophores and Their Applications for Hit Discovery , 2008, J. Chem. Inf. Model..

[91]  Darren Vs Green,et al.  Virtual screening of chemical libraries for drug discovery , 2008, Expert opinion on drug discovery.

[92]  Yu-Quan Wei,et al.  Towards more accurate pharmacophore modeling: Multicomplex-based comprehensive pharmacophore map and most-frequent-feature pharmacophore model of CDK2. , 2008, Journal of molecular graphics & modelling.

[93]  Jonathan W. Essex,et al.  A review of protein-small molecule docking methods , 2002, J. Comput. Aided Mol. Des..

[94]  Thomas Lengauer,et al.  FlexE: efficient molecular docking considering protein structure variations. , 2001, Journal of molecular biology.

[95]  Jürgen Bajorath,et al.  Development of a Fingerprint Reduction Approach for Bayesian Similarity Searching Based on Kullback-Leibler Divergence Analysis , 2009, J. Chem. Inf. Model..

[96]  George Karypis,et al.  Common Pharmacophore Identification Using Frequent Clique Detection Algorithm , 2009, J. Chem. Inf. Model..

[97]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[98]  Petra Schneider,et al.  Scaffold Hopping by “Fuzzy” Pharmacophores and its Application to RNA Targets , 2007, Chembiochem : a European journal of chemical biology.

[99]  Benjamin Parent,et al.  Optimized Evolutionary Strategies in Conformational Sampling , 2006, Soft Comput..

[100]  Timothy Clark,et al.  An analytical, variable resolution, complete description of static molecules and their intermolecular binding properties. , 2005, Journal of chemical information and modeling.

[101]  Dimitris K. Agrafiotis,et al.  Recursive Distance Partitioning Algorithm for Common Pharmacophore Identification , 2007, J. Chem. Inf. Model..

[102]  Bjørn K. Alsberg,et al.  An alignment‐free methodology for modelling field‐based 3D‐structure activity relationships using inductive logic programming , 2007 .

[103]  Dragos Horvath,et al.  Strengths and Limitations of Pharmacophore‐Based Virtual Screening , 2005 .

[104]  Anna Linusson,et al.  SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.

[105]  Robert D. Clark,et al.  Parameterization and Conformational Sampling Effects in Pharmacophore Multiplet Searching , 2008, J. Chem. Inf. Model..

[106]  Stephen Muggleton,et al.  Scaffold Hopping in Drug Discovery Using Inductive Logic Programming , 2008, J. Chem. Inf. Model..

[107]  David T Manallack,et al.  The use of local surface properties for molecular superimposition , 2008, Journal of molecular modeling.

[108]  Matthias Rarey,et al.  Beyond the Virtual Screening Paradigm: Structure-Based Searching for New Lead Compounds , 2009, J. Chem. Inf. Model..

[109]  Olivier Sperandio,et al.  MED-SuMoLig: A New Ligand-Based Screening Tool for Efficient Scaffold Hopping , 2007, J. Chem. Inf. Model..

[110]  Masilamani Elizabeth Sobhia,et al.  Fingerprint Directed Scaffold Hopping for Identification of CCR2 Antagonists , 2008, J. Chem. Inf. Model..

[111]  Hyunah Choo,et al.  Identification of novel serotonin 2C receptor ligands by sequential virtual screening. , 2009, Bioorganic & medicinal chemistry.

[112]  J. A. Grant,et al.  Gaussian docking functions. , 2003, Biopolymers.

[113]  Simone Sciabola,et al.  Pharmacophoric Fingerprint Method (TOPP) for 3D-QSAR Modeling: Application to CYP2D6 Metabolic Stability , 2007, J. Chem. Inf. Model..

[114]  Sune Askjaer,et al.  Combining Pharmacophore Fingerprints and PLS-Discriminant Analysis for Virtual Screening and SAR Elucidation , 2008, J. Chem. Inf. Model..

[115]  Robert D. Clark,et al.  A marriage made in torsional space: using GALAHAD models to drive pharmacophore multiplet searches , 2007, J. Comput. Aided Mol. Des..

[116]  Dragos Horvath,et al.  Neighborhood Behavior of in Silico Structural Spaces with Respect to In Vitro Activity Spaces-A Benchmark for Neighborhood Behavior Assessment of Different in Silico Similarity Metrics , 2003, J. Chem. Inf. Comput. Sci..

[117]  Peter Willett,et al.  GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D , 2006, J. Comput. Aided Mol. Des..

[118]  Johan Wouters,et al.  Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. , 2009, Bioorganic & medicinal chemistry.

[119]  Rajarshi Guha,et al.  Structure-Activity Landscape Index: Identifying and Quantifying Activity Cliffs , 2008, J. Chem. Inf. Model..

[120]  Santosh Putta,et al.  Feature-map vectors: a new class of informative descriptors for computational drug discovery , 2007, J. Comput. Aided Mol. Des..

[121]  Lester A. Mitscher,et al.  Glossary of terms used in medicinal chemistry , 1998 .

[122]  Osman Güner,et al.  Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. , 2004, Current medicinal chemistry.

[123]  Jia Jia,et al.  Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries. , 2009, Combinatorial chemistry & high throughput screening.

[124]  Paul Langan,et al.  X-ray structure of the ternary MTX.NADPH complex of the anthrax dihydrofolate reductase: a pharmacophore for dual-site inhibitor design. , 2009, Journal of structural biology.

[125]  Ji-Xia Ren,et al.  Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. , 2009, Journal of molecular graphics & modelling.

[126]  Gilles Marcou,et al.  Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..

[127]  Heather A Carlson,et al.  Exploring experimental sources of multiple protein conformations in structure-based drug design. , 2007, Journal of the American Chemical Society.

[128]  Herbert Köppen Virtual screening - what does it give us? , 2009, Current opinion in drug discovery & development.

[129]  G. T. Gunnarsson,et al.  On designing non-saccharide, allosteric activators of antithrombin. , 2009, European journal of medicinal chemistry.